ArticleScientific reports2025
Evaluation of Clareon Vivity and PureSee intraocular lenses: optical quality, depth of focus and misalignment effects.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinical Performance After Implantation of a New Purely Refractive Extended Depth of Field Intraocular Lens in Cataract Patients.Clinical ophthalmology (Auckland, N.Z.) · 2026Trial
- Comparing Visual Outcomes Between Two Extended Depth-of-Focus Intraocular Lenses in an Asian Population.Diagnostics (Basel, Switzerland) · 2026Article
- Patient-reported outcome measures after non-diffractive extended range of field IOL implantation: PureSee versus Vivity.Acta ophthalmologica · 2026Article
- Influence of angle kappa and angle alpha on visual outcomes after implantation of a nondiffractive extended-depth-of-focus intraocular lens: a prospective observation study.BMC ophthalmology · 2026Observational
- An Update on Intraocular Lens Technology for Presbyopia Correction and Visual Outcomes.Medical sciences (Basel, Switzerland) · 2026Review
- Visual function comparison of a non-diffractive extended depth-of-focus and an enhanced monofocal intraocular lens sharing the same platform.Scientific reports · 2026Article
- A Retrospective Study: Comparative Visual Performance of Two Non-Diffractive Extended Depth-of-Focus Intraocular Lenses: TECNIS PureSee versus Clareon Vivity.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Early Visual Performance and Subjective Experience After Bilateral Implantation of a Novel Fully Refractive Extended Depth of Focus Intraocular Lens.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Comparison of U.S. FDA premarket approval studies between two non-diffractive extended depth of focus lenses (AcrySof IQ Vivity versus TECNIS PureSee).Medical hypothesis, discovery & innovation ophthalmology journal · 2026Article
- Comparative Visual Performance and Optical Stability of Clareon Vivity and TECNIS PureSee EDoF IOLs in Cataract Patients.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Factors that affect distance-corrected near visual acuity in partial range of focus intraocular lenses.Scientific reports · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended depth of focus (EDoF) intraocular lenses allow cataract and refractive-lens-exchange patients to have improved vision at an intermediate distance. Two EDoF lenses, Clareon Vivity and Tecnis PureSee, were evaluated for optical quality using the OptiSpheric IOL Pro2 according to ISO 11979-2 guidelines and measured using Modulation Transfer Function (MTF) and 1951 USAF resolution test chart at 3.0- and 4.5-mm apertures. The IOLs' tolerance to 0.50 mm decentration and a 5° tilt were tested. The unwanted visual effects were compared using their light distribution at 4.5 mm aperture beyond a polychromatic point spread function center. The two models demonstrated comparable optical qualities at intermediate and far focuses; the predicted visual acuities for the Vivity and PureSee were respectively - 0.04 versus - 0.05logMAR at 0 diopter and 0.05 versus 0.07logMAR at - 1.50 diopters of defocus. Increasing pupil size decreased both lenses' optical quality. While decentration decreased the optical quality of both models, tilt had less of an effect. Both were similar in introducing minimal unwanted side effects through visualizing a halo pattern. The results indicate that these lenses offer a good option for patients interested in EDoF lenses and future clinical studies should contribute further insight into their performance and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.